medRxiv preprint doi: https://doi.org/10.1101/2023.04.03.23288067; this version posted September 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 1

1 To be submitted to <u>Genome Biology</u>

2 Enhancing Infectious Intestinal Disease diagnosis through metagenomic and

3 metatranscriptomic sequencing of over 1000 human diarrhoeal samples

- 4 Edward Cunningham-Oakes^{1,2}, Blanca M. Perez-Sepulveda³, Yan Li³, Jay C. D. Hinton³,
- 5 Charlotte A. Nelson⁴, K. Marie McIntyre⁵, Maya Wardeh^{6,7,8}, Sam Haldenby⁴, Richard
- 6 Gregory⁴, Miren Iturriza-Gómara^{3,9}, Christiane Hertz-Fowler⁴, Sarah J. O'Brien⁵, Nigel A.
- 7 Cunliffe^{2,3}, Alistair C. Darby^{1,2,4*}; on behalf of the INTEGRATE consortium
- 8 ¹Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK
- 9 ²NIHR Health Protection Research Unit in Gastrointestinal Infections, Liverpool, UK
- ³Department of Clinical Infection, Microbiology and Immunology, Institute of Infection,
 Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
- ⁴Centre for Genomic Research, Institute of Systems, Molecular and Integrative Biology,
 University of Liverpool, Liverpool, UK
- ⁵School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK
- 15 ⁶Department of Computer Science, University of Liverpool, Liverpool, UK
- ⁷Department of Livestock and One Health, Institute of Infection, Veterinary and Ecological
 Sciences, University of Liverpool, Liverpool, UK
- 18 ⁸Department of Mathematics, University of Liverpool, Liverpool, UK
- ⁹Centre for Vaccine Innovation and Access, Program for Appropriate Technology in Health
- 20 (PATH), Geneva, 1218, Switzerland
- 21 ^{*}For correspondence:
- 22 E-mail: <u>Alistair.Darby@liverpool.ac.uk</u>

23 Abstract

- 24 Fundamental issues in the traditional surveillance of diarrhoeal disease need to be addressed.
- 25 The limitations of traditional microbiological diagnostic methods often mean that the cause of
- 26 diarrhoea remains unknown, especially for novel or difficult-to-isolate pathogens. Sequencing

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Cunningham-Oakes et al. 2024

samples directly, without isolating pathogens, would address this issue. However, we must
ensure that sequencing also captures pathogens that are detectable using current diagnostic
methods.

30 We show that metagenomic and metatranscriptomic approaches can effectively detect nine 31 gastrointestinal pathogens in the UK. Metatranscriptomics shows increased sensitivity of 32 detection for pathogens like Campylobacter, Clostridioides difficile, Cryptosporidium and 33 Giardia, while metagenomics is more effective for detecting pathogens such as Adenovirus, 34 pathogenic Escherichia coli, Salmonella, Shigella, and Yersinia enterocolitica. Certain 35 pathogens were detected by both metagenomic and metatranscriptomic sequencing. 36 Metatranscriptomics gave near-complete genome coverage for Human mastadenovirus F and 37 detected Cryptosporidium via capture of Cryptosporidium parvum virus (CSpV1). A 38 comprehensive transcriptomic profile of Salmonella Enteritidis was recovered from the stool 39 of a patient with a laboratory-confirmed Salmonella infection.

40 This study highlights the power of direct sequencing of human samples to augment GI 41 pathogen surveillance and clinical diagnostics. Metatranscriptomics was best for capturing a 42 wide breadth of pathogens and was more sensitive for this purpose. We propose that 43 metatranscriptomics should be considered for future surveillance of gastrointestinal 44 pathogens. This study has generated a rich data resource of paired metagenomic and 45 metatranscriptomic datasets, direct from over 1000 patient stool samples. We have made 46 these data publicly available to promote the improved understanding of pathogens associated 47 with infectious intestinal diseases.

48 Keywords

49 microbiome, culture-independent, metagenome, metatranscriptome, diagnostics, genomics,

50 pathogens.

51 Background

The incidence of infectious intestinal disease (or acute gastroenteritis) is estimated to be 18 million cases each year in the United Kingdom (UK)[1]. About 25% of infected people experience diarrhoeal and related gastrointestinal symptoms. The current mainstay for identifying gastrointestinal pathogens in faecal specimens in the UK are conventional laboratory techniques, including microscopy and antigen detection, and increasingly, molecular assays such as nucleic acid amplification[2].

Although conventional and polymerase chain-reaction (PCR)-based approaches (such as 58 59 BioFire Panels) are validated for clinical laboratory use[2], both focus on a single gene or set of characteristics providing limited information about pathogens[3]. In the case of bacterial 60 culture, the time required for growth, lack of sensitivity, and the challenge of culturing fastidious 61 62 organisms cause diagnostic delays[3]. Current methods lack the sensitivity required to detect 63 pathogens that are present intermittently or in low numbers[4]. In contrast, PCR-based 64 methods use target sequences for organism detection, resulting in increased sensitivity and 65 no strict requirement for the prior growth of organisms[3].

66 Whilst PCR-based methods are more sensitive than conventional (traditional) methods, they 67 lack resolution[5] and are unable to achieve the strain-level discrimination required for 68 outbreak monitoring[6]. Inevitably, molecular assays target known genes from well-69 characterised organisms [5], meaning that unexpected pathogens and unique genes will be 70 missed. Whole-genome sequencing partly overcomes this, but still requires the isolation of a 71 pure culture of pathogenic organisms.

All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 4

The speed and sensitivity of metagenomic and metatranscriptomic data analysis[7] has been significantly enhanced by k-mer-based methods, an approach that has been widely adopted in many popular workflows[8,9] to identify pathogens in metagenomic samples through database matching. The computational efficiency of k-mers is ideal for high-throughput sequencing applications[10]. However, it is important to note that sequencing errors and the comprehensiveness of the databases used[11] can influence the effectiveness of k-mer-based approaches.

It has been proposed that DNA and RNA sequencing of clinical samples could be a valuable future approach[5]. To ensure that the presence of pathogens is recorded accurately, it is essential to understand the strengths and limitations of metagenomic and metatranscriptomic approaches.

83 The INTEGRATE study[12] compared traditional (culture, ELISA, microscopy and PCR) 84 diagnostic methods with state-of-the-art, sensitive molecular and genome-based 85 microbiological methods for identifying and characterising causative pathogens[12]. Here, we 86 present data generated by next-generation sequencing of the stool microbiomes of 1.067 87 patients with symptoms of gastroenteritis. This dataset represented a unique opportunity to 88 explore the effectiveness of k-mer-based analyses using a large number of samples that were also characterised with gold-standard clinical laboratory diagnostics. We considered the 89 90 comparative benefits of different sequencing types in various scenarios (right test, right time, 91 right patient).

We use these data to show that both metagenomic (DNA) and metatranscriptomic (RNA) sequencing directly from stool can detect the major community-associated gastrointestinal (GI) pathogens in the United Kingdom. We found that metagenomic and metatranscriptomic

Cunningham-Oakes et al. 2024

INTEGRATE

Page 5 |

95 sequencing have distinctive features for pathogen detection, and discovered that 96 metatranscriptomics offers unexpected benefits for pathogen surveillance.

All of these data have been made publicly available (PRJEB62473) to provide 97 a rich data 98 source for researchers to foster a deeper understanding of the pathogens associated with 99 infectious intestinal diseases.

100 Results

101 Metagenomics and metatranscriptomics show different levels of sensitivity for GI 102 pathogens

103 The DNA and RNA from a total of 1,067 samples were sequenced, with 985 providing both 104 metagenomic and metatranscriptomic data (see Supplementary File 1 for all k-mer counts and 105 associated taxonomy from these samples). For Campylobacter, Cryptosporidium, and Giardia 106 (Figure 1), metatranscriptomics showed greater sensitivity than metagenomics (see Methods 107 for definition of sensitivity). In contrast, metagenomics displayed greater sensitivity than 108 metatranscriptomics for the Adenoviridae, Clostridium difficile, pathogenic Escherichia coli, 109 Salmonella, Shigella and Yersinia enterocolitica (Figure 1). Entamoeba histolytica were not 110 detected in either the metagenomic or metatranscriptomic datasets.

111 The detection of GI pathogens in metagenomic and metatranscriptomic data mirrors 112 clinical laboratory results

113 Our analysis showed that the pathogens detected in sequencing reads closely match results 114 generated by laboratory diagnostics for Adenovirus, C. difficile, Campylobacter, 115 Cryptosporidium, Norovirus, Rotavirus, Salmonella, Sapovirus, Shigella, and Y. enterocolitica 116 (Figure 2). Most major GI community pathogens in the United Kingdom were detected in both metagenomic and metatranscriptomic data, but RNA viruses could only be detected by 117

118 metatranscriptomics. A summary of the "traditional" methods used for pathogen diagnosis in119 the INTEGRATE study is presented in Table 1.

120 Viral pathogens

121 **DNA** viruses such as Adenovirus were detected in both the metagenomic and 122 metatranscriptomic datasets. For Adenovirus, positive correlations were observed between 123 detection in metagenomic reads, metatranscriptomic reads, and Luminex xTAG 124 Gastrointestinal Pathogen Panel (Luminex) results (p<0.001). The metatranscriptomic results 125 correlated positively with Rotavirus (p<0.001). The detection of Norovirus and Sapovirus by 126 metatranscriptomics was significantly correlated (p<0.001) with the Luminex results. 127 Metagenomic and metatranscriptomic results did not correlate with the detection of Astrovirus 128 using Traditional and Luminex methods.

129 **Protists**

Protists were detected by both metagenomics and metatranscriptomics. However, the metatranscriptomic results had a much higher sensitivity for the detection of parasites than metagenomics. Positive correlations between the detection of *Cryptosporidium* in metatranscriptomic data and laboratory data were highly significant (p<0.001). No associations were observed between metagenomic data and laboratory results for *Cryptosporidium*. There was no correlation between the detection of *Giardia* using Traditional or Luminex methods, and detecting *Giardia* using metagenomics or metatranscriptomics.

137 Bacterial pathogens

The identification of bacterial pathogens from sequencing data is challenging, as commensal organisms and pathogens can have extremely high levels of genomic similarity. Laboratory diagnostics tend to differentiate commensal and pathogenic organisms using genes or

perpetuity. All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 7

141 phenotypes associated with pathogenicity. Our results show that metagenomics and 142 metatranscriptomics can both identify bacterial pathogens with differing sensitivities. For 143 Campylobacter, positive correlations were observed between direct sequencing and all 144 laboratory results (p<0.001). Salmonella displayed positive correlations between sequencing 145 data and both Traditional (p<0.001) and Luminex (p<0.25) diagnostics. C. difficile 146 metatranscriptomic sequencing data positively correlated with both Traditional (p<0.25) and 147 Luminex (p<0.001) diagnostics. Y. enterocolitica sequencing data positively correlated with Luminex results as follows: C. difficile metatranscriptomic reads (p<0.001), Y. enterocolitica 148 149 metatranscriptomic reads (p<0.01), and Y. enterocolitica metagenomic reads (p<0.001).

E. coli and *Shigella* are closely-related species; detection of *Shigella* in metagenomic data correlated positively with traditional and Luminex diagnostics (p<0.25), while *E. coli* showed a non-significant correlation (p>0.25). *Vibrio cholerae* were not be detected in either metagenomic or metatranscriptomic data, consistent with laboratory diagnostics, which identified no *V. cholerae* infections.

A summary of all correlations between the detection of GI pathogens in sequencing reads and
laboratory data and their significance is provided in Supplementary Files 2 and 3.

Page 8

Test Parameter	Liverpool	Manchester	Preston
Adenovirus 41/42	PCR	PCR	Immunoassay
Rotavirus A	PCR	PCR	Immunoassay
Norovirus GI/GII	PCR	PCR	Immunoassay & PCR
Sapovirus	PCR	PCR	Not Available
Clostridioides difficile toxin A/B & GDH	Immunoassay	Immunoassay	Immunoassay
Salmonella	Culture	Culture	Culture
Shigella	Culture	Culture	Culture
Campylobacter (C. jejuni, C. coli, C lari)	Culture	Culture	Culture
E. coli O157	Culture	Culture	Culture
Enterotoxigenic <i>E. coli</i> (ETEC) LT/ST	Not Available	Not Available	Not Available
Enteroaggregative E.coli	Not Available	Not Available	Not Available
Yersinia enterocolitica	Culture	Culture	Not Available
Vibrio cholerae	Culture	Culture	Culture
Shigella like toxin producing E.coli (STEC)	Not Available	Not Available	Not Available
Giardia lamblia	Microscopy	Immunoassay	Immunoassay
Cryptosporidium	Microscopy	Immunoassay	Immunoassay
Entamoeba histolytica	Microscopy	Місгоѕсору	Microscopy

Table 1: Summary of "traditional" methods used at clinical laboratories during the INTEGRATE study. Samples were processed via routine diagnostic pathways at each laboratory involved in the study (see Supplementary File 5). Traditional assays for Enterotoxic and Enteroaggregative *E. coli*, as well as *E. coli* O157, were not available (only available in the Luminex xTAG GPP panel).

All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 9

157 **Case-studies for the use of metatranscriptomics in pathogen surveillance**

158 **Complete genomes from diarrhoeal-associated Adenovirus can be detected in both** 159 **metagenomic and metatranscriptomic data**

160 Whilst Adenovirus is a DNA virus, it was surprising to see that Adenovirus could also be 161 detected in RNA. There was a strong correlation between the detection of Adenovirus in 162 metagenomic and metatranscriptomic data, and detection using Luminex methods (see 163 Supplementary File 2 and Figure 2). Mapping of Adenovirus-associated reads to the Human 164 mastadenovirus F genome showed that, in 7 out of 9 samples, metagenomics generated more 165 complete genes, at a higher depth (Supplementary File 4). However, in 2 out of 9 samples 166 (Samples 5638 and 6985) near-complete genome coverage was achieved using both 167 metagenomics and metatranscriptomics (83.9-100% - Supplementary File 4 and Figure 3). 168 These results demonstrate the potential of metatranscriptomics to directly capture the virome 169 from clinical samples, including DNA viruses relevant to the condition of interest.

170 Cryptosporidium-associated RNA viruses facilitate detection directly from stool

171 Another interesting observation was the correlation (p<0.001, see Figure 2) between the 172 detection of Cryptosporidium using metatranscriptomics and the detection of Cryptosporidium 173 in the laboratory. In contrast, detecting Cryptosporidium using metagenomics did not correlate 174 with laboratory results. Mapping revealed that Cryptosporidium was accurately identified in metatranscriptomic data due to the presence of Cryptosporidium parvum virus (CSpV1), which 175 176 is an RNA virus. CSpV1 was identified in 33 metatranscriptomic samples (Table 2). Of these 177 33 samples, 9 received a positive result using Traditional methods, whilst 16 were positive by Luminex. CSpV1 received a high-confidence score (0.995) in 21 out of the 33 samples, with 178 179 percentage breadth of genome coverage ranging from 57.1-100%. This illustrates the potential 180 of CSpV1 to be used as a reliable biomarker for human Cryptosporidium infection.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.03.23288067; this version posted September 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 10

Study ID	Traditional result	Luminex result	TAXID	Read count	Coverage breadth (%)	Coverage depth (fold)	PanGIA score
238	0	1	675060.1	24334	0.9937	1057.6231	0.995
299	0	1	675060.1	17324	0.9907	742.9534	0.995
347	0	1	675060.1	18914	0.9513	820.9334	0.995
1530	NA	0	675060.1	132778	0.9997	5789.0705	0.995
1730	0	1	675060.1	277178	1	12099.0436	0.995
1868	1	1	675060.1	25942	0.9836	1121.2385	0.995
1996	NA	0	675060.1	490	0.9659	21.2555	0.995
2237	0	0	675060.1	54	0.5705	2.3751	0.995
2270	1	1	675060.1	2481486	1	108131.0308	0.995
4580	0	0	675060.1	136	0.8757	5.711	0.995
4667	1	1	675060.1	45590	1	1975.986	0.995
4922	1	1	675060.1	11154	0.9438	474.8819	0.995
5019	1	1	675060.1	27990	0.997	1230.6458	0.995
5195	0	0	675060.1	526	0.8951	22.775	0.995
5215	1	1	675060.1	43408	0.9997	1895.0209	0.995
5563	0	1	675060.1	85048	0.9988	3700.396	0.995
5675	0	1	675060.1	8338	0.9913	360.4002	0.995
6446	1	1	675060.1	2200	0.9668	94.7941	0.995
6602	0	1	675060.1	5770	0.9949	250.243	0.995
6912	1	1	675060.1	21542	0.8655	932.6551	0.995
7233	1	1	675060.1	22898	1	1005.3114	0.995
1817	NA	0	675060.1	14	0.2624	0.601	0.601
1548	0	0	675060.1	12	0.2585	0.535	0.535
1111	NA	0	675060.1	10	0.2409	0.4471	0.4471
769	NA	0	675060.1	10	0.2445	0.439	0.439
1436	NA	0	675060.1	6	0.1491	0.2687	0.2687
54	0	0	675060.1	6	0.1626	0.2469	0.2469
127	0	NA	675060.1	4	0.0819	0.1793	0.1793
6890	NA	0	675060.1	4	0.1136	0.179	0.179
5734	0	0	675060.1	4	0.0562	0.1787	0.1787
360	0	0	675060.1	4	0.1482	0.1781	0.1781
2279	0	0	675060.1	4	0.0855	0.1614	0.1614
369	0	0	675060.1	4	0.1384	0.1599	0.1599

Table 2: Identification of CSpV1 in metatranscriptomic data in comparison to results from *Cryptosporidium* **laboratory diagnostics.** For both Traditional and Luminex results, NA represents instances where a diagnostic test could not be performed.

INTEGRATE

Cunningham-Oakes et al. 2024

Page 11 I

181 Generation of a complete transcriptomic profile for Salmonella

182 Metatranscriptomic analysis of stool from a patient with a laboratory-confirmed Salmonella 183 infection yielded functional insights that cannot be achieved with Traditional and Luminex 184 diagnostics. Transcriptomic analysis reveals gene expression patterns that key biological 185 processes in bacteria. The high-quality transcriptomic profile was generated from 12.7 million 186 sequence reads that mapped to the genome of S. enterica serovar Enteritidis PT4 strain 187 P125109. The S. Enteritidis transcripts from this novel gene expression data can be visualised 188 and interrogated in a bespoke genome browser (https://s.hintonlab.com/study_74).

189 A variety of environmentally responsive Salmonella genes were highly expressed (as defined 190 by Kröger et al. 2013; Cell Host Microbe [13]), likely reflecting physicochemical stresses the 191 bacteria had been exposed to in the stool sample. Examples include ahpC (oxidative stress), 192 hmpA (nitrosative stress), phoH (phosphate starvation), pspA (extracytoplasmic stress), and 193 the rpoE and rpoS transcription factor genes, as can be seen with the SalComMac data 194 visualisation tool. The unexpected discovery that the metatranscriptomic analysis of a human 195 stool sample can generate a comprehensive gene expression profile of a Salmonella pathogen 196 is worthy of future exploitation.

197 Discussion

198 We have demonstrated that metagenomic and metatranscriptomic approaches provide 199 agnostic detection of important UK GI pathogens from human stool. The primary impact of this 200 work lies within GI pathogen diagnostics. Our findings demonstrate the potential for improving 201 current GI pathogen diagnostics and the bridging of gaps not addressed by standard 202 approaches.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 12

203 Improvements within the scope of current diagnostics

Sequencing directly from stool could minimise the time required for pathogen detection, allowing more laborious detection methods such as cultivation to be appropriately tailored to confirm the presence of the suspected pathogens.

207 The metatranscriptomic strategy displays increased sensitivity for Campylobacter, C. difficile, 208 Cryptosporidium and Giardia, whilst metagenomics displayed increased sensitivity for other 209 GI pathogens including Adenovirus, pathogenic E. coli, Salmonella, Shigella, and Y. 210 enterocolitica. Direct extraction of RNA from stool represents a single sample format and 211 cultivation-independent process for detecting a broad range of GI pathogens, including 212 unexpected aetiological agents and those that cannot be detected by metagenomic 213 sequencing, such as RNA viruses. The observation of near-complete genome coverage for 214 Human mastadenovirus F in both the metagenome and metatranscriptome highlights the 215 potential to optimise metatranscriptomic sequencing from stool to capture the virome, 216 including DNA virus transcriptomes relevant to clinical conditions. This finding is supported by 217 previous clinical studies, which used metatranscriptomics to simultaneously measure the 218 virome, microbiome, and host response[14]. Our data and previous studies[15] confirm the 219 ability to characterise disease-related microbiomes with increased sensitivity via 220 metatranscriptomics.

221 Increased sensitivity for the detection of protists of concern in GI infections was also 222 demonstrated. Our visualisations of metagenomic and metatranscriptomic reads (Figure 1) 223 showed that metatranscriptomic data provide greater sensitivity for detecting Cryptosporidium 224 and Giardia (protists). Finally, our multivariable model demonstrated the strong correlation and 225 high significance between the detection of Cryptosporidium in the laboratory, and in 226 metatranscriptomic data, a finding that was supported by a previous study that detected 23% 227 more blood infections than traditional methods[16]. In these data, the presence of 228 Cryptosporidium-associated viruses increases the sensitivity of detection for this particular

medRxiv preprint doi: https://doi.org/10.1101/2023.04.03.23288067; this version posted September 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

protist. In contrast, the detection of *Cryptosporidium* using metagenomics appears to be spurious. This virus has recently been reported in various subtypes of *Cryptosporidium parvum* from diarrhoeic farm animals[17,18], but it is not currently used as a diagnostic marker in humans. These results highlight the advantages of metatranscriptomics for *Cryptosporidium* surveillance, where the use of metagenomics alone could result in missed identification. This suggests that RNA viruses could be considered sensitive biomarkers for *Cryptosporidium* and other protists.

Overall, our findings reveal that RNA is a valuable diagnostic target for the detection of pathogens of low abundance and reduces false-positive signals from commensals. Our approach could influence the future allocation of resources for reference laboratory diagnostics.

240 Bridging gaps not addressed by current diagnostics

241 Metatranscriptomic data could fill gaps in areas of clinical relevance that are not fulfilled by 242 routine clinical diagnostics. Firstly, metagenomic and metatranscriptomic data permits the 243 identification of multiple species and strains within a sample (Supplementary Figure 1, 244 Supplementary File 4), including novel pathogens. Such analysis is beyond the scope of our 245 study, but has been used to successfully identify novel pathogens from the stools of various 246 mammalian species [19,20]. Additionally, we have demonstrated the ability to rapidly generate 247 gene expression profiles for pathogens of concern, without prior enrichment. Finally, we have 248 generated illuminating metatranscriptomic data from a human diarrhoeal sample. Future 249 studies could generate true disease-state expression profile by using appropriate 250 methodology. From a clinical perspective, the use of metagenomic and metatranscriptomic 251 sequencing has the potential to reveal the effects of interventions[21] and to accurately 252 investigate host-pathogen dynamics during genuine human infections[14].

Cunningham-Oakes et al. 2024

INTEGRATE

Page 14

253 Limitations

In certain scenarios, metagenomic sequencing captures more information than metatranscriptomic sequencing. For DNA viruses, while it is possible to capture expression profiles, optimisation is needed to improve this process. Our data demonstrate that the underlying biology can be captured, but further refinement is necessary. Additionally, *E. histolytica* was not captured by metagenomic or metatranscriptomic approaches, a finding that requires further investigation.

Future adaptation of our workflow is needed for the accurate identification of E. coli 260 261 pathovariants from sequencing data. Shigella and E. coli pathovariants are extremely similar 262 on a genome-wide (and taxonomic) level[22], and are currently distinguished using specific 263 gene-based assays[23]. In contrast, our study drew correlations between pathogens in reads 264 and laboratory tests based on taxonomy. Due to this approach, and the ubiquitous presence 265 of E. coli in all stool samples, it was not possible to associate the presence of E. coli, and 266 gene-based assays used for E. coli pathovariant identification (Supplementary Table S1, 267 Supplementary File 4). This may explain the limited overlap between Shigella sequencing reads and laboratory tests (Figure 2), due to the conflation of Shigella with E. coli (and vice 268 269 versa) in our current analysis. Future work should also validate this approach on a range of 270 sample types (beyond stool) to ensure robustness and reliability across different clinical 271 scenarios.

272 Perspective

With sufficient benchmarking, the diagnosis of various GI pathogens can be achieved from clinical samples without culturing. Metatranscriptomics can detect active DNA viruses and enhance sensitivity for protists by using RNA viruses as biomarkers. Perhaps the value of clinical metagenomics has been overstated, and metatranscriptomics could offer a comprehensive approach to both detect disease-relevant pathogens and understand their biology.

INTEGRATE

Cunningham-Oakes et al. 2024

Page 15

279 To our knowledge, this study is the first to demonstrate and quantify the benefits that 280 metatranscriptomics could bring to gastrointestinal surveillance in the United Kingdom by 281 direct comparison of all major community pathogens to validated diagnostics. Our study lays 282 the groundwork for the implementation of sequencing-based diagnostics in clinical settings, 283 with the potential to detect a broader range of organisms than current approaches and to 284 identify novel pathogens.

285 Materials and methods

Patient recruitment and sample collection 286

287 Recruitment and sample collection was described previously[12]. Briefly, stool was collected 288 from 1.067 members of the public with symptoms of acute gastroenteritis via practices in the 289 Royal College of General Practitioners Research and Surveillance Centre National Monitoring 290 Network (RCGP RSC NMN). Patients meeting inclusion criteria were invited to submit a stool 291 sample for microbiological analysis. Consent was obtained for this procedure, as stool 292 sampling is usually only performed if a case is severe, or persistent. Patients who provided a 293 stool sample were then recruited into the study.

294 Sample processing

295 Faecal samples were received by one of three clinical laboratories (Royal Liverpool and 296 Broadgreen University Hospitals NHS Trust, Central Manchester University Hospitals NHS 297 Foundation Trust, or Lancashire Teaching Hospitals NHS Foundation Trust), and divided into 298 two aliquots. One part of the sample was processed using traditional methods (culture, ELISA, 299 microscopy or PCR with no additional hybridisation probe – see Supplementary File 5) at each 300 laboratory; the other was processed using a combined molecular multiplex real-time 301 polymerase chain reaction (PCR) and target-specific hybridisation probe [Luminex xTAG Gastrointestinal Pathogen Panel, Luminex, I032C0324], supplemented with targets for 302 303 Enteroaggregative Escherichia coli and Sapovirus. Nucleic acid extraction from faeces was

INTEGRATE

Cunningham-Oakes et al. 2024

Page 16 I

304 performed using QIASymphany and EasyMag automated nucleic acid extraction platforms. 305 Further details can be found in the primary study protocol[12]. Samples that returned a positive 306 result according to routine clinical practice were designated as "clinical positive". Those that 307 returned a positive result by Luminex were designated as "molecular positive".

308 Metagenomic and metatranscriptomic sequencing

309 Illumina fragment libraries from DNA were prepared using NEBNext DNA Ultra kits. For the 310 generation of dual-indexed, strand-specific RNASeg libraries, RiboZero rRNA depleted RNA 311 samples were prepared using NEBNext Ultra Directional RNA kits. For all libraries, paired-312 end, 150-bp sequencing was then performed on an Illumina HiSeg 4000, generating data from 313 >280 million clusters per lane.

314 Quality control for second-generation sequencing reads

315 Modules from the MetaWRAP[24] (v1.3.2) pipeline were used to standardise metagenome 316 analysis. The pipeline was deployed in a dedicated Conda environment, using the "manual 317 installation" guide (see GitHub). All paired-end reads underwent guality-control using the 318 MetaWRAP "read gc" module to remove low-quality, adapter, and human sequence reads. 319 The T2T consortium complete human genome, (GCF_009914755.1) and human 320 mitochondrial genome (NC_012920.1) were used as references for the removal of human 321 reads.

322 Assigning taxonomy to genomic DNA and RNA reads and assessing microbiome 323 diversity

324 DNA and RNA reads were used for taxonomic assignments with Kraken2[8] (v2.1.2), using a 325 custom database, which included all RefSeq complete genomes and proteins for archaea, 326 bacteria, fungi, viruses, plants, protozoa, as well as all complete RefSeq plasmid nucleotide 327 and protein sequences, and a false-positive minimised version of the NCBI UniVec database.

INTEGRATE

Cunningham-Oakes et al. 2024

Page 17

328 A confidence threshold of 0.1 was set for read assignments, and reports were generated for 329 downstream biom file generation. For DNA sequencing data, read counts assigned to 330 taxonomies in each sample were then re-estimated using the average read length of that 331 sample, using Bracken[25] (v2.0). Kraken-biom (v1.0.1) was then used to generate biom file 332 in json format, using initial Kraken reports for RNA samples, and Bracken reports for DNA 333 samples. Biom (v2.1.6) was then used to assign tabulated metadata to this biom file.

334 Visualisation and comparison of taxa of interest in RNA and DNA

335 A taxonomy table was generated from the biom file in R (v4.2.2) using Phyloseg[26] (v1.42.0) 336 and MicrobiotaProcess[27] (v1.10.3). Read-assigned taxonomy counts were parsed from this 337 table for any samples with both metagenomic (DNA) and metatranscriptomic data (n=985). 338 Counts were extracted for the following taxa: Adenoviridae, Campylobacter, Clostridioides 339 difficile (C. difficile), Cryptosporidium, Escherichia coli (E. coli), Norovirus, Rotavirus, 340 Salmonella, Shigella, Sapovirus, Vibrio cholerae (V. cholerae) and Yersinia enterocolitica (Y. 341 enterocolitica). These taxa were chosen to reflect the pathogen panels used during this study. 342 RNA virus (Astrovirus, Norovirus, Rotavirus, and Sapovirus) read counts could not be 343 extracted for this part of the analysis, as visualisations relied on the presence of DNA reads. 344 DNA and RNA counts were log-transformed and plotted against one another as a line graph 345 using standard functions in gpplot2[28] (v3.4.0). Visualisations were then used to assess the 346 sensitivity of metagenomics and metatranscriptomics for the selected taxa, where we define sensitivity as the skew of data points towards either metagenomics (x-axis) or 347 metatranscriptomics (y-axis). A 0,0 intercept line was included in each line graph to assist in 348 349 illustrating sensitivity differences.

350 Correlation of genomic reads assigned to taxa of interest with number of observed taxa and results from laboratory diagnostics 351

352 Associations between read counts and laboratory results for organisms of interest were 353 assessed using a multivariable linear regression model in MaAsLin 2[29] (v1.6.0) under default medRxiv preprint doi: https://doi.org/10.1101/2023.04.03.23288067; this version posted September 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

INTEGRATE

perpetuity. All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

Page 18

354 settings. The introduction of another variable into the model (laboratory results) provided a 355 point of reference. This allowed us to determine the relationship between any sample with 356 sequencing data and laboratory results. As such, for this analysis, all sequenced patient 357 samples (n = 1,067) were used, even if they did not contain both metagenomic and 358 metatranscriptomic data. Our approach allowed RNA virus read counts from 359 metatranscriptomic data to be included in this analysis. To visualise the strength of correlations 360 between laboratory results and pathogen-assigned sequencing reads, correlation coefficients 361 and adjusted p-values from the model were tabulated and used to generate a heatmap with 362 corrplot (v0.9.2). Adjusted p-values were generated using the Benjamini-Hochberg Procedure.

363 Comparative analysis of Adenovirus-associated k-mers in DNA and RNA

The extract_kraken_reads.py utility from Kraken-tools (v1.2) was used alongside Kraken2 reports to extract reads with k-mer profiles associated with the family *Adenoviridae* for samples that tested positive using either traditional or Luminex methods. Samples where sequencing was not successful for both DNA and RNA were excluded from this analysis.

These reads were then mapped to the Human Mastadenovirus F genome (Accession: GCF_000846685.1) using HISAT2[30] (v2.2.1) for splice-aware mapping. Coverage statistics were then generated using samtools coverage. Coverage statistics for each sample were compiled into a single table and visualised as a bar chart using ggplot2 (v3.4.0).

372

INTEGRATE

Cunningham-Oakes et al. 2024

Page 19 I

373 Identification of CSpV1 as a biomarker of Cryptosporidium infection

To understand why Cryptosporidium-associated k-mers showed a positive correlation with 374 375 using gold-standard diagnostics in metatranscriptomic but not metagenomic sequencing data, we employed competitive mapping using PanGIA[31] (v1.0.0-RC6.2). We mapped quality-376 377 controlled reads from all INTEGRATE samples against a database containing representative 378 and reference genomes of bacteria, archaea, and viruses in NCBI RefSeq (release 89). This 379 helped to validate our k-mer-based results and offers a less computationally intensive 380 alternative to mapping-based approaches for future users of k-mer-based databases. By 381 aligning the reads to these genome sequences, we obtained a read count and depth of 382 coverage for each organism. We then extracted entries associated with the term 'Cryptosporidium' along with their corresponding scores and mapping information. PanGIA 383 384 also accounts for many reads mapped equally well to other organisms and the percentage of 385 identity of these hits and derived a confidence score from this, ranging from 0 to 1 for each 386 query sequence at each taxonomy level. This allowed us to determine the certainty that the 387 organism is truly present in the sequencing data.

Visualisation of a Salmonella transcriptome directly from stool 388

389 Metatranscriptomic reads from a sample of a patient with a later-confirmed (culture positive) 390 Salmonella spp. infection underwent quality control, alignment, and quantification using the 391 Bacpipe RNA-seq processing pipeline (v0.6.0). The GFF annotation[32] for the Salmonella 392 serovar Enteritidis PT4 strain P125109 enterica subsp. enterica (Accession: 393 GCA_015240635.1) was used in this analysis. Coverage tracks and annotation were 394 visualised JBrowse (v1.16.8). This visualisation using can be found here: 395 https://s.hintonlab.com/study 74.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 20

Declarations 396

397 Ethics approval and consent to participate

398 Members of the public with symptoms of acute gastroenteritis, including a case definition of 399 vomiting and diarrhoea, who sought health advice from general practices in the RCGP RSC 400 NMN were invited to submit a stool sample for microbiological examination. Their consent for 401 this procedure was sought because normal care would not necessarily entail stool sampling 402 for most patients unless their symptoms were severe or had persisted for a long time. The 403 North West - Greater Manchester East Research Ethics Committee (REC reference: 404 15/NW/0233) and NHS Health Research Authority (HRA) Confidential Advisory Group (CAG) 405 (CAG reference: 15/CAG/0131) granted a favourable ethics opinion for the INTEGRATE 406 project. Approval was also granted by NHS Research Management and Governance 407 Committees (including Royal Liverpool and Broadgreen University Hospital Trust, Lancashire 408 Teaching Hospitals NHS Foundation Trust, Central Manchester University Hospitals NHS 409 Foundation Trust, and the University of Liverpool Sponsor), the Lancaster University Faculty 410 of Health and Medicine Ethics Committee, and the University of Liverpool Ethics Sub-411 Committees. An Information Governance Toolkit (IGT) from the Department of Health hosted 412 by the Health and Social Care Information Centre (HSCIC) was also completed for the project, 413 and all project research staff obtained Honorary NHS contracts, research passports, and 414 letters of access, as necessary.

Consent for publication 415

416 The publication was approved by the National Institute for Health and Care Research on 29th 417 March 2023.

418 Availability of data and materials

419 Illumina sequence reads with human data removed have been deposited in the European 420 Nucleotide Archive (ENA) under ENA project accession number PRJEB62473.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 21

421 Competing interests

M.I.G. has received research grants from GSK and Merck, and has provided expert advice to
GSK. M.I.G. has been an employee of GSK since January 2023, although the work presented
here was completed prior to this date.

425 *Funding*

426 This publication presents independent research supported by the Health Innovation Challenge 427 Fund (WT096200, HICF-T5-354), a parallel funding partnership between the Department of 428 Health and Wellcome Trust. The views expressed in this publication are those of the author(s) 429 and not necessarily those of the Department of Health or Wellcome Trust. This study is also funded by the National Institute for Health Research (NIHR) Health Protection Research Unit 430 431 in Gastrointestinal Infections at University of Liverpool, in partnership with the UK Health 432 Security Agency (UKHSA), in collaboration with University of Warwick. E.C.-O., N.A.C. and 433 A.C.D. are based at The University of Liverpool. The views expressed are those of the 434 author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or 435 the UK Health Security Agency. N.A.C. is a NIHR Senior Investigator (NIHR203756).

436 This work was supported by a Wellcome Trust Investigator award (grant number437 222528/Z/21/Z) to J.C.D.H.

438 Authors' contributions

439 Conceptualisation: E.C.-O. and A.C.D. Data curation: E.C.-O., B.P-S., M.W., C.A.N., K.M.M.,

440 S.H. and R.G. Formal analysis: E.C.-O. and Y.L. Funding acquisition: S.J.O'B. and N.A.C.

- 441 Investigation: E.C.-O. and A.C.D. Project administration: E.C.-O., M.I.G., C.H.-F., S.J.O'B.,
- 442 N.A.C. and A.C.D. Resources: Y.L., B.P-S., J.C.D.H., C.A.N., C.H.-F. and A.C.D. Supervision:
- 443 N.A.C. and A.C.D. Validation: E.C.-O. Visualisation: E.C.-O. and Y.L. Writing original draft:
- 444 E.C.-O., B.P-S., J.C.D.H., N.A.C. and A.C.D. Writing review and editing: all authors.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.03.23288067; this version posted September 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

INTEGRATE

perpetuity. All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

Page 22

445 Acknowledgements

The authors thank the members of the INTEGRATE Consortium. The INTEGRATE 446 447 Consortium investigators in the United Kingdom are Sarah J O'Brien (principal investigator), Frederick J Bolton, Rob M Christley, Helen E Clough, Nigel A Cunliffe, Susan Dawson, 448 449 Elizabeth Deja, Ann E Durie, Sam Haldenby, Neil Hall, Christiane Hertz-Fowler, Debbie 450 Howarth, Lirije Hyseni, Miren Iturriza-Gómara, Kathryn Jackson, Lucy Jones, Trevor Jones, K Marie McIntyre, Charlotte A Nelson, Lois Orton, Jane A Pulman, Alan D Radford, Danielle 451 452 Reaves, Helen K Ruddock, Darlene A Snape, Debbi Stanistreet, Tamara Thiele, Maya 453 Wardeh, David Williams, and Craig Winstanley (University of Liverpool), Kate Dodd (NIHR 454 Clinical Research Network: North West Coast), Peter J Diggle, Alison C Hale, Barry S 455 Rowlingson (Lancaster University), Jim Anson, Caroline E Corless, Viki Owen (Royal 456 Liverpool and Broadgreen University Hospitals NHS Trust), Malcolm Bennett (University of 457 Nottingham), Lorraine Bolton, John Cheesbrough, Katherine Gray, David Orr, Lorna Wilson 458 (Lancashire Teaching Hospitals NHS Foundation Trust), Andrew R Dodgson, Ashley McEwan 459 (Manchester University NHS Foundation Trust), Paul Cleary, Alex J Elliot, Ken H Lamden, 460 Lorraine Lighton, Catherine M McCann, Matthieu Pegorie, Nicola Schinaia, Anjila Shah, Gillian 461 E Smith, Roberto Vivancos, Bernard Wood (PHE), Rikesh Bhatt, Dyfrig A Hughes (Bangor University), Rob Davies (APHA); Simon de Lusignan, Filipa Ferreira, Mariya Hriskova, Sam 462 463 O'Sullivan, Stacy Shinneman and Ivelina Yonova (University of Surrey/Royal College of 464 General Practitioners).

All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 23

465 References

- 466 1. Foodborne Disease Estimates for the United Kingdom in 2018. Food Standards Agency;467 2020. Available from:
- 468 https://webarchive.nationalarchives.gov.uk/ukgwa/20200803160512/https://www.food.gov.uk
- 469 /sites/default/files/media/document/foodborne-disease-estimates-for-the-united-kingdom-in-470 2018.pdf. Accessed 09 Sep 2024.
- 471
- 472 2. Public Health England, NHS. UK Standards for Microbiology Investigations -
- 473 Gastroenteritis. UK Government; 2020. Available from:
- 474 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_da
 475 ta/file/930517/S_7i2_FINAL-UKSMI.pdf. Accessed 09 Sep 2024.
- 476 3. Foddai ACG, Grant IR. Methods for detection of viable foodborne pathogens: current
 477 state-of-art and future prospects. *Appl Microbiol Biotechnol*. 2020;104:4281–8.
- 478 4. Kanagarajah S, Waldram A, Dolan G, Jenkins C, Ashton PM, Carrion Martin AI, et al.
- 479 Whole genome sequencing reveals an outbreak of Salmonella Enteritidis associated with
- 480 reptile feeder mice in the United Kingdom, 2012-2015. Food Microbiology. 2018;71:32-8.
- 481 5. Chiu CY, Miller SA. Clinical metagenomics. *Nat Rev Genet*. 2019;20:341–55.
- 482 6. Buytaers FE, Saltykova A, Mattheus W, Verhaegen B, Roosens NHC, Vanneste K, *et al.*483 Application of a strain-level shotgun metagenomics approach on food samples: resolution of
- 484 the source of a *Salmonella* food-borne outbreak. *Microb Genom*. 2021;7:000547.
- 7. Moeckel C, Mareboina M, Konnaris MA, Chan CSY, Mouratidis I, Montgomery A, *et al.* A
 survey of k-mer methods and applications in bioinformatics. *Comput Struct Biotechnol J.*2024;23:2289–303.
- 488 8. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome
 489 *Biol.* 2019;20:257.
- 490 9. Juul S, Izquierdo F, Hurst A, Dai X, Wright A, Kulesha E, *et al.* What's in my pot? Real491 time species identification on the MinION[™]. *bioRxiv*. 2015;030742.
- 492 10. Breitwieser FP, Lu J, Salzberg SL. A review of methods and databases for metagenomic
 493 classification and assembly. *Brief Bioinform*. 2019;20:1125–36.
- 494 11. Van Etten J, Stephens TG, Bhattacharya D. A k-mer-Based Approach for Phylogenetic
 495 Classification of Taxa in Environmental Genomic Data. Systematic Biology. 2023;72:1101–
 496 18.
- 497 12. McIntyre KM, Bolton FJ, Christley RM, Cleary P, Deja E, Durie AE, *et al.* A Fully
 498 Integrated Real-Time Detection, Diagnosis, and Control of Community Diarrheal Disease
 499 Clusters and Outbreaks (the INTEGRATE Project): Protocol for an Enhanced Surveillance
 500 System. *JMIR Res Protoc.* 2019;8:e13941.
- 501 13. Kröger C, Colgan A, Srikumar S, Händler K, Sivasankaran SK, Hammarlöf DL, *et al.* An
 502 Infection-Relevant Transcriptomic Compendium for *Salmonella enterica* Serovar
 503 Typhimurium. *Cell Host & Microbe*. 2013;14:683–95.
- 14. Rajagopala SV, Bakhoum NG, Pakala SB, Shilts MH, Rosas-Salazar C, Mai A, *et al.* Metatranscriptomics to characterize respiratory virome, microbiome, and host response
 directly from clinical samples. *Cell Rep Methods*. 2021;1:100091.

All rights reserved. No reuse allowed without permission.

Cunningham-Oakes et al. 2024

INTEGRATE

Page 24

507 15. Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, *et al.* Metagenomic and
 508 metatranscriptomic analysis of human prostate microbiota from patients with prostate
 509 cancer. *BMC Genomics*. 2019;20:146.

510 16. Galen SC, Borner J, Williamson JL, Witt CC, Perkins SL. Metatranscriptomics yields new
 511 genomic resources and sensitive detection of infections for diverse blood parasites. *Mol Ecol* 512 *Resour.* 2020;20:14–28.

513 17. Adjou KT, Chevillot A, Lucas P, Blanchard Y, Louifi H, Arab R, *et al.* First identification of
514 Cryptosporidium parvum virus 1 (CSpV1) in various subtypes of *Cryptosporidium parvum*515 from diarrheic calves, lambs and goat kids from France. *Vet Res.* 2023;54:66.

516 18. Chae J-B, Shin S-U, Kim S, Jo Y-M, Roh H, Chae H, *et al.* The First Identification of
517 *Cryptosporidium parvum* Virus-1 (CSpV1) in Hanwoo (*Bos taurus coreanae*) Calves in
518 Korea. *Vet Sci.* 2023;10.

519 19. Geldenhuys M, Mortlock M, Weyer J, Bezuidt O, Seamark ECJ, Kearney T, et al. A
520 metagenomic viral discovery approach identifies potential zoonotic and novel mammalian
521 viruses in *Neoromicia* bats within South Africa. *PLoS One*. 2018;13:e0194527.

522 20. Vibin J, Chamings A, Klaassen M, Bhatta TR, Alexandersen S. Metagenomic
523 characterisation of avian parvoviruses and picornaviruses from Australian wild ducks. *Sci*524 *Rep.* 2020;10:12800.

525 21. Qin H, Lo NW-S, Loo JF-C, Lin X, Yim AK-Y, Tsui SK-W, et al. Comparative

transcriptomics of multidrug-resistant *Acinetobacter baumannii* in response to antibiotic
 treatments. *Sci Rep.* 2018;8:3515.

528 22. Parks DH, Chuvochina M, Reeves PR, Beatson SA, Hugenholtz P. Reclassification of
529 Shigella species as later heterotypic synonyms of *Escherichia coli* in the Genome Taxonomy
530 Database. *bioRxiv*. 2021;2021.09.22.461432.

531 23. Devanga Ragupathi NK, Muthuirulandi Sethuvel DP, Inbanathan FY, Veeraraghavan B.
532 Accurate differentiation of *Escherichia coli* and *Shigella* serogroups: challenges and
533 strategies. *New Microbes New Infect.* 2018;21:58–62.

534 24. Uritskiy GV, DiRuggiero J, Taylor J. MetaWRAP—a flexible pipeline for genome-resolved 535 metagenomic data analysis. *Microbiome*. 2018;6:158.

536 25. Lu J, Breitwieser F, Thielen P, Salzberg S. Bracken: Estimating species abundance in 537 metagenomics data. *PeerJ Comput Sci.* 2017;3:e104.

538 26. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis 539 and Graphics of Microbiome Census Data. *PLoS One*. 2013;8:e61217.

540 27. Xu S, Zhan L, Tang W, Wang Q, Dai Z, Zhou L, *et al.* MicrobiotaProcess: A
541 comprehensive R package for deep mining microbiome. *The Innovation*. 2023;4:100388.

542 28. Valero-Mora PM. ggplot2: Elegant Graphics for Data Analysis. J Stat Soft. 2010;35:1–3.

543 29. Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, et al. Multivariable

association discovery in population-scale meta-omics studies. *PLoS Comput Biol.*2021;17:e1009442.

All rights reserved. No reuse allowed without permission. 2024 INTEGRATE

Cunningham-Oakes et al. 2024

Page 25

546 30. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and 547 genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol*. 2019;37:907–15.

548 31. Li P-E, Russell JA, Yarmosh D, Shteyman AG, Parker K, Wood H, *et al.* PanGIA: A
549 Metagenomics Analytical Framework for Routine Biosurveillance and Clinical Pathogen
550 Detection. *bioRxiv*. 2020;2020.04.20.051813.

32. Perez-Sepulveda BM, Predeus AV, Fong WY, Parry CM, Cheesbrough J, Wigley P, et
 al. Complete Genome Sequences of African Salmonella enterica Serovar Enteritidis Clinical
 Isolates Associated with Bloodstream Infection. Microbiol Resour Announc. 2021;10.

554 **Figure legends**

555 **Figure 1: Visual overview and comparison of DNA (metagenomic) and RNA** 556 **(metatranscriptomic) sequencing reads** assigned to GI pathogens of relevance to the UK 557 setting. For all graphs, the dashed (black) intercept line is provided to highlight the skew of 558 sensitivity towards either DNA or RNA.

Figure 2: Statistically significant correlations were observed between sequencing data
and laboratory tests for 10 out of 14 major GI community pathogens in the United
Kingdom. Results where at least one statistically significant correlation was observed are
shown. All correlations, whether significant or not, are displayed in Supplementary Figure 1.
No statistically significant correlation was found between the sequencing and diagnostic test
for Astrovirus, *E. histolytica*, *Giardia* or *V. cholerae*.

The darker the colour of a quadrant in a heatmap, the stronger the correlation (coefficient) between the detection of a pathogen in sequencing data (metagenomic or metatranscriptomic) and a laboratory result (Luminex or Traditional). Asterisks in quadrants indicate the statistical significance of correlations as follows: *: p < 0.25; **: p < 0.05; ***: p < 0.01; ****: p < 0.001.

570 **Figure 3: Adenovirus can be detected through its genomic material and the expression** 571 **of transcript, directly from stool**. Graphs display the breadth of coverage (%) for both DNA 572 (purple) and RNA (orange) across nine samples, chosen on the basis of positive results 573 through gold-standard laboratory methods. Coverage values were generated via mapping to 574 a representative Human mastadenovirus F genome (GCF_000846685.1, International 575 Committee on Taxonomy of Viruses species exemplar).

576 **Supplementary Figure 1:** Complete overview of correlations observed between sequencing 577 data and laboratory tests for major GI community pathogens in the United Kingdom 578 (alternative to Figure 2).



.1.		METAGENOMIC Traditional Luminex		METATRANSCRIPTOMIC Traditional Luminex	
DNA	Adenovirus		****		****
RNA	Norovirus				****
	Rotavirus			****	****
	Sapovirus				****
	Clostridioides difficile			*	*
RACTERIA	Campylobacter	****	****	****	****
	Salmonella	****	*	****	*
	Shigella	*	*		
	Yersinia enterocolitica			****	***
DOTICT	Cryptosporidium			****	****
	No association Low	CORRELATION LEVEL	High) < 0.25 **p < 0.05 ***p	o < 0.01 **** p < 0.001



DNA RNA



Positive or negative correlation (Coefficient value)

Key for significance values: * = <0.25, ** = <0.05, *** = <0.01, **** = <0.001